8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Jan 27, 2026·SEC
Cognition Therapeutics, Inc.(CGTX)Earnings, Financials & Key Ratios
CGTX•NASDAQ
$1.23
$91M mkt cap·Price updated May 6, 2026
AboutCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.Show more
- Revenue$0
- EBITDA-$48M+11.4%
- Net Income-$23M+30.9%
- EPS (Diluted)-0.32+62.4%
- ROE-88.6%+43.6%
- Debt/Equity0.02-57.1%
- Interest Coverage-3676.85-170.8%
CGTX Key Insights
Cognition Therapeutics, Inc. (CGTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 18.5% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 83.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CGTX Price & Volume
Cognition Therapeutics, Inc. (CGTX) stock price & volume — 10-year historical chart
Loading chart...
CGTX Growth Metrics
Cognition Therapeutics, Inc. (CGTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.68%
Return on Capital
10 Years-242.49%
5 Years-153.96%
3 Years-191.11%
Last Year-178.49%
CGTX Recent Earnings
Cognition Therapeutics, Inc. (CGTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 26, 2026EPS
$0.02
Est $0.06
+66.7%
Revenue
—
Q4 2025
Nov 6, 2025EPS
$0.06
Est $0.07
+14.3%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.11
Est $0.12
+8.3%
Revenue
—
Q2 2025
May 7, 2025EPS
$0.14
Est $0.12
-16.7%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.02vs $0.06+66.7% | — |
| Q4 2025 | Nov 6, 2025 | $0.06vs $0.07+14.3% | — |
| Q3 2025 | Aug 7, 2025 | $0.11vs $0.12+8.3% | — |
| Q2 2025 | May 7, 2025 | $0.14vs $0.12-16.7% | — |
Based on last 12 quarters of dataView full earnings history →
CGTX Peer Comparison
Cognition Therapeutics, Inc. (CGTX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 ATHA | 17.12M | 4.34 | -0.17 | -340.97% | 0.03 | |||
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ESPR | 753.05M | 3.15 | -28.64 | 21.31% | -5.63% | |||
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare CGTX vs Peers
Cognition Therapeutics, Inc. (CGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CGTX Income Statement
Cognition Therapeutics, Inc. (CGTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 81K | 98K | 0 | 235K | 0 | 0 | 228K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -81K▲ 0% | -98K▼ 21.0% | 0▲ 100.0% | -235K▲ 0% | 0▲ 100.0% | 0▲ 0% | -228K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -20.99% | 100% | - | 100% | - | - |
| Operating Expenses | 4.67M | 17.31M | 28.6M | 43.32M | 50.72M | 53.97M | 47.8M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.45M | 4.52M | 10.03M | 13.23M | 13.53M | 12.29M | 10.61M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 14.38M | 12.89M | 18.57M | 30.32M | 37.2M | 41.68M | 37.19M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | -13.16M | -98K | 0 | -235K | 0 | 0 | 0 |
| Operating Income | -17.83M▲ 0% | -17.41M▲ 2.4% | -28.6M▼ 64.3% | -43.55M▼ 52.3% | -50.72M▼ 16.5% | -53.97M▼ 6.4% | -47.8M▲ 11.4% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 2.38% | -64.29% | -52.29% | -16.47% | -6.39% | 11.43% |
| EBITDA | -17.75M | -17.31M | -28.5M | -43.32M | -50.47M | -53.7M | -47.57M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | 2.48% | -64.68% | -51.96% | -16.52% | -6.4% | 11.41% |
| D&A (Non-Cash Add-back) | 81K | 98K | 93K | 235K | 252K | 266K | 228K |
| EBIT | -3.82M | -6.09M | -10.82M | -21.37M | -25.76M | -33.95M | -47.8M |
| Net Interest Income | 12.14M | 9.1M | 16.55M | 22.19M | 27K | -25K | -13K |
| Interest Income | 13.16M | 10.86M | 17.45M | 22.22M | 27K | 0 | 0 |
| Interest Expense | 1.02M | 1.75M | 893K | 28K | 0 | 25K | 13K |
| Other Income/Expense | 0 | 9.57M | 16.88M | 22.15M | 24.94M | 20M | 24.31M |
| Pretax Income | -4.84M▲ 0% | -7.84M▼ 61.9% | -11.72M▼ 49.5% | -21.4M▼ 82.6% | -25.79M▼ 20.5% | -33.97M▼ 31.7% | -23.49M▲ 30.9% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | -22.15M | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 103.54% | 0% | 0% | 0% |
| Net Income | -6.95M▲ 0% | -10.07M▼ 44.9% | -11.72M▼ 16.3% | 757K▲ 106.5% | -25.79M▼ 3506.6% | -33.97M▼ 31.7% | -23.49M▲ 30.9% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -44.86% | -16.32% | 106.46% | -3506.6% | -31.73% | 30.86% |
| Net Income (Continuing) | -4.84M | -7.84M | -11.72M | 757K | -25.79M | -33.97M | -23.49M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.32▲ 0% | -0.55▼ 71.9% | -0.73▼ 32.7% | -0.74▼ 1.4% | -0.86▼ 16.2% | -0.85▲ 1.2% | -0.32▲ 62.4% |
| EPS Growth % | - | -71.88% | -32.73% | -1.37% | -16.22% | 1.16% | 62.35% |
| EPS (Basic) | -0.32 | -0.55 | -0.73 | -0.74 | -0.86 | -0.85 | -0.32 |
| Diluted Shares Outstanding | 21.94M | 21.94M | 22.23M | 28.99M | 30.03M | 39.73M | 72.77M |
| Basic Shares Outstanding | 21.94M | 21.94M | 22.23M | 28.99M | 29.99M | 39.73M | 72.77M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
CGTX Balance Sheet
Cognition Therapeutics, Inc. (CGTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.16M | 6.91M | 58.99M | 47.65M | 34.22M | 29.55M | 47.99M |
| Cash & Short-Term Investments | 2.89M | 5.19M | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M |
| Cash Only | 2.89M | 5.19M | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 4.12M | 1.15M | 2.27M | 3.67M | 1.28M | 2.69M | 9.92M |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 117K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 527.22 | - | - | - | - | - | - |
| Other Current Assets | -88K | 23K | 11K | 0 | 3.02M | 0 | 1.26M |
| Total Non-Current Assets | 299K | 211K | 145K | 2.78M | 941K | 679K | 399K |
| Property, Plant & Equipment | 299K | 211K | 145K | 1.05M | 941K | 679K | 399K |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 1.73M | 0 | 0 | 0 |
| Total Assets | 7.46M▲ 0% | 7.12M▼ 4.6% | 59.14M▲ 730.7% | 50.42M▼ 14.7% | 35.16M▼ 30.3% | 30.23M▼ 14.0% | 48.39M▲ 60.1% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | -4.56% | 730.69% | -14.73% | -30.27% | -14.02% | 60.05% |
| Total Current Liabilities | 3.68M | 3.25M | 7.86M | 7.79M | 10.17M | 11.14M | 13.92M |
| Accounts Payable | 2.36M | 2M | 4.17M | 3.22M | 3.69M | 1.98M | 1.12M |
| Days Payables Outstanding | 10.62K | 7.46K | - | 5K | - | - | 1.79K |
| Short-Term Debt | 0 | 0 | 0 | 634K | 544K | 279K | 443K |
| Deferred Revenue (Current) | 1.32M | 0 | 753K | 1.7M | 1.7M | 1.07M | 367K |
| Other Current Liabilities | -531K | 985K | 2.48M | 870K | 1.17M | 1.53M | 11.99M |
| Current Ratio | 1.94x | 2.13x | 7.50x | 6.11x | 3.37x | 2.65x | 3.45x |
| Quick Ratio | 1.91x | 2.13x | 7.50x | 6.11x | 3.37x | 2.65x | 3.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 62.2M | 72.05M | 0 | 2.38M | 520K | 342K | 195K |
| Long-Term Debt | 6.9M | 12.85M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 695K | 520K | 342K | 195K |
| Deferred Tax Liabilities | 0 | 0 | 0 | -695K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 55.3M | 59.2M | 0 | 695K | 0 | 0 | 0 |
| Total Liabilities | 65.88M | 75.3M | 7.86M | 10.18M | 10.69M | 11.48M | 14.12M |
| Total Debt | 6.9M | 12.85M | 0 | 1.48M | 1.24M | 814K | 638K |
| Net Debt | 4.01M | 7.66M | -54.72M | -40.08M | -28.68M | -24.2M | -36.17M |
| Debt / Equity | - | - | - | 0.04x | 0.05x | 0.04x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -3.73x | -3.48x | -12.12x | -763.18x | - | -1357.84x | -3676.85x |
| Total Equity | -58.42M▲ 0% | -68.18M▼ 16.7% | 51.27M▲ 175.2% | 40.25M▼ 21.5% | 24.47M▼ 39.2% | 18.75M▼ 23.4% | 34.27M▲ 82.8% |
| Equity Growth % | - | -16.71% | 175.2% | -21.5% | -39.19% | -23.39% | 82.78% |
| Book Value per Share | -2.66 | -3.11 | 2.31 | 1.39 | 0.82 | 0.47 | 0.47 |
| Total Shareholders' Equity | -58.42M | -68.18M | 51.27M | 40.25M | 24.47M | 18.75M | 34.27M |
| Common Stock | 1K | 1K | 22K | 29K | 32K | 60K | 90K |
| Retained Earnings | -58.24M | -68.22M | -94M | -115.4M | -141.19M | -175.16M | -198.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -185K | -187K | -198K | -199K | -195K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGTX Cash Flow Statement
Cognition Therapeutics, Inc. (CGTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.1M | -3.43M | -3.63M | -18.53M | -16.02M | -28.47M | -24.59M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -10.81% | -5.77% | -410.41% | 13.57% | -77.76% | 13.65% |
| Net Income | -4.84M | -7.84M | -11.72M | -21.4M | -25.79M | -33.97M | -23.49M |
| Depreciation & Amortization | 81K | 98K | 93K | 235K | 252K | 266K | 228K |
| Stock-Based Compensation | 361 | 475K | 5.18M | 3.57M | 4.35M | 3.75M | 2.09M |
| Deferred Taxes | 238K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 854.64K | 766K | -33K | 0 | 318K | 195K | 41K |
| Working Capital Changes | 570K | 3.07M | 2.84M | -943K | 4.85M | 1.29M | -3.46M |
| Change in Receivables | -1.12M | 3M | -1.11M | -1.41M | 2.39M | -1.41M | -7.24M |
| Change in Inventory | 1.12M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 862K | -364K | 2.17M | -1.09M | 0 | 0 | 3.51M |
| Cash from Investing | -144K | -10K | -27K | -171K | -147K | -4K | 9K |
| Capital Expenditures | -144K | -10K | -27K | -171K | -147K | -4K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 9K |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.79M | 5.76M | 53.2M | 5.55M | 4.52M | 23.57M | 36.57M |
| Debt Issued (Net) | 2.83M | 5.72M | -268K | -1.4M | -811K | -739K | -353K |
| Equity Issued (Net) | 0 | 47K | 44.22M | 5.32M | 5.33M | 24.35M | 37.09M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -34K | 0 | 9.25M | 1.62M | 0 | -46K | -164K |
| Net Change in Cash | -508K▲ 0% | 2.3M▲ 552.6% | 49.53M▲ 2054.5% | -13.16M▼ 126.6% | -11.64M▲ 11.5% | -4.91M▲ 57.8% | 11.99M▲ 344.1% |
| Free Cash Flow | -3.24M▲ 0% | -3.44M▼ 6.2% | -3.66M▼ 6.2% | -18.7M▼ 411.3% | -16.16M▲ 13.6% | -28.48M▼ 76.2% | -24.59M▲ 13.7% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -6.2% | -6.24% | -411.32% | 13.57% | -76.17% | 13.66% |
| FCF per Share | -0.15 | -0.16 | -0.16 | -0.65 | -0.54 | -0.72 | -0.34 |
| FCF Conversion (FCF/Net Income) | 0.45x | 0.34x | 0.31x | -24.48x | 0.62x | 0.84x | 1.05x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CGTX Key Ratios
Cognition Therapeutics, Inc. (CGTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -22.85% | 1.65% | -79.69% | -157.19% | -88.6% |
| Return on Invested Capital (ROIC) | - | - | - | -19795.91% | - | - | - |
| Debt / Equity | - | - | - | 0.04x | 0.05x | 0.04x | 0.02x |
| Interest Coverage | -3.73x | -3.48x | -12.12x | -763.18x | - | -1357.84x | -3676.85x |
| FCF Conversion | 0.45x | 0.34x | 0.31x | -24.48x | 0.62x | 0.84x | 1.05x |
CGTX SEC Filings & Documents
Cognition Therapeutics, Inc. (CGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CGTX Frequently Asked Questions
Cognition Therapeutics, Inc. (CGTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cognition Therapeutics, Inc. (CGTX) grew revenue by 0.0% over the past year. Growth has been modest.
Cognition Therapeutics, Inc. (CGTX) reported a net loss of $23.5M for fiscal year 2025.
Dividend & Returns
Cognition Therapeutics, Inc. (CGTX) has a return on equity (ROE) of -88.6%. Negative ROE indicates the company is unprofitable.
Cognition Therapeutics, Inc. (CGTX) had negative free cash flow of $24.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More CGTX
Cognition Therapeutics, Inc. (CGTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates